MedTrace Logo

Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD

NCT00403442 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2008-07-30

No results posted yet for this study

Summary

The purpose of this study is to explore the combination of PDT with verteporfin at reduced and standard fluence rates, in conjunction with bevacizumab, in the treatment of subfoveal CNV of all subtypes with a high percentage of subretinal hemorrhage (hemorrhage \>50% of total lesion area).

To assess the safety of bevacizumab in combination with verteporfin PDT (reduced fluence: 300 mW/cm2) as compared to bevacizumab in combination with verteporfin PDT (standard fluence: 600 mW/cm2) in patients whose neovascular CNV lesions containing \>50% blood.

Conditions

  • Macular Degeneration

Interventions

DEVICE

Verteporfin Therapy/ Drug: Bevacizumab

Sponsors & Collaborators

  • QLT Inc.

    collaborator INDUSTRY

  • Vitreous -Retina- Macula Consultants of New York

    lead OTHER

Principal Investigators

  • Jason S Slakter, M.D. · Vitreous Retina Macula Consultants of New York, P.C.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00403442 on ClinicalTrials.gov